This inventor holds 1 USPTO granted patent. Top assignees: Cellular Biomedicine Group (Shanghai) Ltd., Cellular Biomedicine Group (Wuxi) Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 4 
1 out of 4 Years Active: 2026
Title: Jiaping He: Innovator in Chimeric Antigen Receptor Technology
Introduction
Jiaping He is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biomedical engineering, particularly in the development of chimeric antigen receptors (CARs). His work focuses on enhancing the efficacy of T cell therapies for cancer treatment.
Latest Patents
Jiaping He holds a patent titled "Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof." This patent represents a crucial advancement in targeted cancer therapies, specifically for conditions involving CD20 antigen.
Career Highlights
Throughout his career, Jiaping He has worked with notable companies in the biotechnology sector. He has been associated with Cellular Biomedicine Group (Shanghai) Ltd. and Cellular Biomedicine Group (Wuxi) Ltd. His experience in these organizations has allowed him to contribute to innovative research and development in cellular therapies.
Collaborations
Jiaping He has collaborated with esteemed colleagues in his field, including Yihong Yao and Jiaqi Huang. These partnerships have fostered a collaborative environment that promotes groundbreaking research and development.
Conclusion
Jiaping He is a key figure in the advancement of chimeric antigen receptor technology, with a focus on improving cancer treatment methodologies. His contributions and collaborations continue to shape the future of biomedical engineering.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile